Isabl leverages advanced genomic technologies to provide comprehensive cancer diagnostics through its proprietary Isabl GxT platform. This innovative technology enables the analysis of 100% of the tumor genome and transcriptome, allowing for the detection of all cancer-associated mutations, including those that are often missed by traditional panel-based tests. By integrating data from both cancer and germline DNA, Isabl offers a streamlined diagnostic workflow that delivers actionable insights in clinically relevant timeframes. This holistic approach not only enhances the accuracy of cancer diagnoses but also facilitates novel biomarker discovery, improving treatment planning and patient outcomes.

The company’s commitment to precision medicine is underscored by its collaboration with leading oncologists and cancer centers to evaluate the clinical validity of its tests across various cancer types. Isabl's technology is designed to address the limitations of current sequencing methods, which typically provide insight into only a small fraction of the genome. By focusing on comprehensive genomic analysis, Isabl aims to eliminate diagnostic odysseys and empower healthcare providers with the right data to deliver personalized care. With FDA Breakthrough Device Designation, Isabl is positioned to transform cancer diagnostics and treatment strategies, ultimately enhancing the patient experience and outcomes in oncology.

United States

Isabl integrates the whole genome and transcriptome to inform cancer care

175 Greenwich St, Isabl, Hana by Industrious - 3 World Trade Center, New York, New York 10007, US

Isabl

Company Details